SA Funds 90% of Its HIV/AIDS Programme – Motsoaledi Highlights Challenges Amid PEPFAR Uncertainty

South Africa continues to bear the brunt of the global HIV/AIDS epidemic, funding 90% of its own antiretroviral (ARV) programme. However, Health Minister Dr Aaron Motsoaledi has raised concerns about the potential impact of the US President’s Emergency Plan for AIDS Relief (PEPFAR) review on South Africa’s health infrastructure. Speaking before the Portfolio Committee on Health, Motsoaledi outlined the challenges and broader funding disparities within the country’s healthcare system.

South Africa’s HIV/AIDS Programme and PEPFAR Review

Currently, the South African government finances the vast majority of its HIV/AIDS programme, with only 10% coming from international sources like the Global Fund. However, the US has launched a 90-day review of PEPFAR funding, assessing whether the programme aligns with American values and objectives.

Motsoaledi clarified that the review is a US government initiative, impacting PEPFAR programmes worldwide, not just in South Africa. He further explained that initial discussions with US officials had taken place, though no concrete decisions had been made. Since there is no American ambassador in South Africa, these discussions were held with a chargé d’affaires, limiting the immediate resolution of concerns.

Restrictions on PEPFAR Funding

During his briefing, Motsoaledi also highlighted specific restrictions on how PEPFAR funding can be used. He pointed out that US funds cannot be allocated for:

• Abortions, regardless of their legal status.
• Surgical procedures for transgender individuals.
• LGBTQI+ initiatives.

These restrictions raise further concerns about the flexibility and inclusivity of South Africa’s HIV/AIDS programme response under the PEPFAR framework.

Challenges in Local ARV Production

Motsoaledi delved into the historical struggles of local ARV production, emphasizing that despite efforts to establish a state-owned pharmaceutical company, South Africa still relies heavily on imports.

In 2011-2012, a cost analysis revealed that producing ARVs domestically would have required an additional R16 billion compared to importing from India. This financial burden made local manufacturing unfeasible at the time. Additionally, South African pharmaceutical companies must import Active Pharmaceutical Ingredients (APIs) from India and China, further driving up costs.

The Role of PEPFAR in South Africa’s HIV/AIDS Workforce

PEPFAR funding supports 15,154 healthcare professionals, including:

• Data capturers
• Professional nurses
• Lay counsellors
• Clinical associates
• Social auxiliary workers
• Pharmacy assistants
• Staff nurses
• Pharmacists

Despite this, the South African government covers the salaries of 256,452 out of the 271,660 healthcare workers managing HIV/AIDS daily. This reinforces the country’s financial commitment to combating the epidemic, even amid potential funding uncertainties.

Funding Disparities in South Africa’s Healthcare System

Motsoaledi drew attention to broader disparities in South African healthcare spending. The country allocates 8.5% of its GDP to health, amounting to R570 billion. However, healthcare expenditure remains disproportionately divided:

• 51% of funds serve only 14-15% of the population (medical aid beneficiaries).
• 49% of funds must cover 86% of South Africans reliant on public healthcare.

Comparatively, other BRICS nations spend a lower percentage of their GDP on healthcare, yet achieve better outcomes due to more equitable resource distribution:

• China: 6.5% of GDP
• Brazil: 7.2% of GDP
• India: 3.5% of GDP

Motsoaledi Advocates for NHI Implementation

The minister reaffirmed that implementing the National Health Insurance (NHI) system could reduce South Africa’s dependence on foreign aid. He cited Brazil’s successful rollout of universal healthcare in 1990 as an example of how South Africa could achieve a more self-sufficient and equitable health system.

Uncertainty Surrounding PEPFAR’s Future in South Africa

While acknowledging PEPFAR’s contributions, Motsoaledi stressed that South Africa should strive for self-reliance. He also confirmed that alternative funding sources, such as the Global Fund, provide additional support.

However, with the 90-day PEPFAR review ongoing, uncertainty looms over the programme’s future funding in South Africa. The final decision will be made in Washington, leaving South African health officials in a precarious position as they await the outcome.

Ensuring Continuity of HIV/AIDS Treatment

Despite these challenges, Motsoaledi reassured that ensuring ARV treatment continuity remains a priority. Disruptions in treatment could lead to drug resistance, endangering both individuals and the broader public health response.

“What we must guarantee is that nobody who’s on ARVs stops, because if that happens, that’s going to be very, very dangerous to individuals and to the country,” Motsoaledi warned.

Also Read: Motsoaledi: SA Government to Support HIV/AIDS Patients Despite US Aid Freeze

South Africa remains deeply invested in combating HIV/AIDS, funding the vast majority of its treatment programme. However, the PEPFAR review adds an element of uncertainty to the country’s HIV/AIDS response. As discussions with US officials continue, South Africa must explore alternative funding strategies to maintain its progress in fighting the epidemic.

The implementation of the NHI and the pursuit of more cost-effective ARV production could offer long-term solutions, ensuring that South Africa maintains an independent and sustainable HIV/AIDS programme.